EquityZen Growth Technology Fund LLC - Series 1737
Raised
$115K
Investors
7
Min Invest
$10,020
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 1737 is a Delaware pooled investment fund vehicle filed by EquityZen Advisors and Philip Haslett, raising $115K from 7 investors under Rule 506(b) and Section 3(c)(1) exemptions with a $10K minimum investment. This entity is part of the EquityZen platform, which operates nearly 1,900 related pre-IPO SPV series.
This pre-IPO fund vehicle uses the standard 506(b)/3(c)(1) exemption structure common to pre-IPO secondary platforms, with a $10K retail-accessible minimum investment threshold. The raise size and investor count are consistent with small single-company SPV structures targeting discrete liquidity events in private growth companies.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Philip Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.